Drilldown: Medicines

None (3) · Cyanocobalamin (vitamin B12) (1) · Ferrous sulfate (1) · Folic acid (folate, pteroylglutamic acid) (1) · Sodium Oxybate (1)

Belsomra (1) · Dayvigo (1) · Feosol, Fer-In-Sol, Slow Fe; mostly generic and OTC (1) · Folvite; mostly generic (1) · Many OTC and Rx; Nascobal (intranasal); generic injection (1) · Quviviq (1) · Xyrem; Xywav (lower-sodium formulation with Ca/Mg/K salts) (1)

Dual orexin receptor antagonist (DORA) (3) · GABAB Agonist; Endogenous GHB receptor agonist (1) · the first approved (1) · [[:Category:B-vitamins|B-vitamin]] (2) · [[:Category:Hematinics|Hematinic]] (3) · [[:Category:Iron_supplements|Iron supplement]] (1) · [[:Category:Vitamins|Vitamin]] (2)

None (4) · Agonist at the metabotropic GABAB receptor and the endogenous γ-hydroxybutyrate (GHB) receptor. Produces deep sleep with increased slow-wave architecture, suppression of REM intrusion, and cataplexy reduction. (1) · Competitive antagonist at OX1R and OX2R. Faster receptor association/dissociation kinetics than suvorexant (~16 sec dissociation vs ~57 sec) hypothesized to support sleep onset, with sufficient duration for maintenance. (1) · Competitive antagonist at OX1R and OX2R. First-in-class DORA. Receptor dissociation slower than lemborexant or daridorexant. (1)

Insomnia (sleep onset and/or maintenance) in adults (FDA-approved August 2014). Also studied for insomnia in mild-moderate Alzheimer disease. (1) · Insomnia (sleep onset and/or maintenance) in adults (FDA-approved Dec 2019) (1) · Insomnia (sleep onset and/or sleep maintenance) in adults (FDA-approved Jan 2022) (1) · '"`UNIQ--vote-0000059A-QINU`"', '"`UNIQ--vote-0000059B-QINU`"' (1) · '"`UNIQ--vote-000005B3-QINU`"', '"`UNIQ--vote-000005B4-QINU`"', '"`UNIQ--vote-000005B5-QINU`"', '"`UNIQ--vote-000005B6-QINU`"' (1) · '"`UNIQ--vote-00000607-QINU`"', '"`UNIQ--vote-00000608-QINU`"', '"`UNIQ--vote-00000609-QINU`"', '"`UNIQ--vote-0000060A-QINU`"' (1) · '"`UNIQ--vote-00000717-QINU`"', '"`UNIQ--vote-00000718-QINU`"', '"`UNIQ--vote-00000719-QINU`"' (1)

0.4 mg PO daily (general prevention); 0.8-1 mg/d in pregnancy; 4 mg/d for women with prior NTD-affected pregnancy; 1 mg/d during methotrexate therapy (1) · 10 mg PO 30 min before bedtime (with ≥7 hours of sleep planned) (1) · 2.25 g at bedtime + 2.25 g 2.5–4 h later; titrate weekly to 6–9 g/night total (1) · 25 mg PO at bedtime (no titration); may increase to 50 mg if 25 mg inadequate (1) · 325 mg PO daily to TID (=65 mg elemental iron/tablet); alternate-day dosing is now favored by hepcidin physiology for better absorption with less GI burden (1) · 5 mg PO at bedtime; may increase to 10 mg if inadequate (1) · Replacement: 1000 mcg IM daily for 1 week, then weekly for 4 weeks, then monthly; or 1000-2000 mcg PO daily (effective even in pernicious anemia via passive diffusion); intranasal 500 mcg weekly (1)

0.4, 0.8, 1 mg OTC; 1 mg Rx; 5 mg/mL injection (1) · 0.5 g/mL oral solution (1) · 100, 250, 500, 1000, 5000 mcg tablets (OTC and Rx); 1000 mcg/mL injection; intranasal spray; sublingual (1) · 25 mg, 50 mg tablets (1) · 325 mg tablets (65 mg elemental Fe); 220 mg/5 mL liquid (44 mg elemental Fe/5 mL); 142 mg/mL drops; OTC and Rx (1) · 5 mg, 10 mg tablets (1) · 5 mg, 10 mg, 15 mg, 20 mg tablets (1)

1 mg/d typical Rx; higher in specific indications (1) · 10 mg/d (1) · 20 mg/d (1) · 50 mg/d (1) · 9 g/night (1) · No strict ceiling; water-soluble vitamin, low toxicity (1) · ~200 mg elemental iron/d typical practical limit (1)

IM (2) · intranasal (1) · IV (2) · Oral (6) · Oral (must be taken in bed; effects within minutes) (1) · SC (2) · sublingual (1)

15–30 min (fasting) (1) · Hematologic response within days (1) · Reticulocyte response at 3-5 days; neurologic recovery weeks to months (and may be incomplete if longstanding) (1) · Reticulocyte response at 7-10 days; hemoglobin rise of ~1 g/dL per 3 weeks (1) · ~30 min (3)

None · 24 hours · 4-6 hours · 12 hours · 6-8 hours · Daily dosing · 8-12 hours · 12-24 hours · Hours · Hours per application · 24 hours (HS dosing) · 24 hours (once-daily dosing) · 24 h · N/A · N/A (replacement) · Variable · ~7-8 hours · 3-5 hours · 4-6 hours (IR); 24 hours (ER) · 6-12 hours

Other values:

Search

30–60 min (1) · N/A (incorporated into hemoglobin and tissue stores) (1) · ~0.5 hours plasma; tissue retention longer (1) · ~12 hours (1) · ~17-19 hours (longer than daridorexant) (1) · ~6 days (plasma); hepatic stores last 3-5 years (1) · ~8 hours (shorter than suvorexant and lemborexant) (1)

10-20% (oral; reduced by food, calcium, antacids, PPIs, tea/coffee; enhanced by ascorbate) (1) · High (oral) (1) · Oral ~1-3% via passive diffusion at high doses (independent of intrinsic factor); IM/SC ~100% (1) · ~25% (high first-pass) (1) · ~44% (1) · ~62% (1) · ~82% (1)

Category C (1) · Limited data; avoid (3) · Routinely supplemented in pregnancy and preconception to prevent neural tube defects.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Routinely supplemented in vegan pregnancies and pernicious anemia.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Routinely used; iron requirements rise substantially in pregnancy and lactation.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

OTC (low-dose) and [[USLegal:Prescription only|Rx-only]] (1 mg, injectable) in US (1) · OTC (low/mid-dose oral) and [[USLegal:Prescription only|Rx-only]] (injection, intranasal) in US (1) · OTC in US (1) · Rx, Schedule IV (US) (3) · Schedule III; REMS-restricted (Schedule I if outside the pharmaceutical channel, same molecule as illicit GHB) (1)